Anticoagulation Strategies in Atrial Fibrillation

被引：4

作者：

Menezes, Arthur R. ^{[1
]}

Artham, Surya ^{[1
]}

Lavie, Carl J. ^{[1
,2
]}

Khatib, Sammy ^{[1
]}

机构：

[1] Univ Queensland, Sch Med, Ochsner Clin Sch, Dept Cardiovasc Dis,John Ochsner Heart & Vasc Ins, New Orleans, LA USA

[2] Pennington Biomed Res Ctr, Dept Prevent Med, Baton Rouge, LA USA

来源：

REVIEWS IN CARDIOVASCULAR MEDICINE | 2012年 / 13卷 / 01期

关键词：

Atrial fibrillation; Stroke; Antithrombotic therapy; Warfarin; SHORT-TERM ANTICOAGULATION; DUAL-ANTIPLATELET THERAPY; STROKE PREVENTION; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; ELECTRICAL CARDIOVERSION; ANTITHROMBOTIC THERAPY; RISK STRATIFICATION; PREDICTING STROKE; FACTOR XA; THROMBOEMBOLIC EVENTS;

D O I：

10.3909/ricm0616

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Atrial fibrillation (AF) is a major risk factor for stroke and systemic embolization, particularly in the elderly. Approximately 2.3 million adults in the United States have AF, and it is projected that this number will increase to approximately 5.6 million individuals by the year 2050, with over 50% aged 80 years or older. Vitamin K antagonists are currently the most widely accepted means of stroke prevention in patients with AF; unfortunately, this method of treatment is not a feasible option for many patients for numerous reasons. This article examines and compares the various newer therapeutic agents that have either been approved by the US Food and Drug Administration or are still in various stages of clinical testing, and provides an overview of established antithrombotic therapies. We also discuss the role of anticoagulation in the setting of cardioversion in patients with AF. (C) 2012 MedReviews(R), LLC

引用

页码：E1 / E13

页数：13

共 50 条

[41] The Business Case for Quality Improvement Oral Anticoagulation for Atrial Fibrillation [J].

Rose, Adam J. ;

Berlowitz, Dan R. ;

Ash, Arlene S. ;

Ozonoff, Al ;

Hylek, Elaine M. ;

Goldhaber-Fiebert, Jeremy D. .

CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2011, 4 (04) :416-424

[42] Efficacy and safety of oral anticoagulation in elderly patients with atrial fibrillation [J].

Cavallari, Ilaria ;

Patti, Giuseppe .

ANATOLIAN JOURNAL OF CARDIOLOGY, 2018, 19 (01) :67-71

[43] Timing of Anticoagulation in Atrial Fibrillation Status Post Cardioembolic Stroke [J].

Core, Ashley ;

Pinner, Nathan ;

Bethea, Brittany ;

Starr, Jessica A. .

JOURNAL OF PHARMACY PRACTICE, 2020, 33 (05) :612-617

[44] Clinical strategies for selecting oral anticoagulants in patients with atrial fibrillation [J].

Pokorney, Sean D. ;

Sherwood, Matthew W. ;

Becker, Richard C. .

JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2013, 36 (02) :163-174

[45] Anticoagulation prescription in atrial fibrillation [J].

Bertomeu-Gonzalez, Vicente ;

Cordero, Alberto ;

Mazon, Pilar ;

Moreno-Arribas, Jose ;

Facila, Lorenzo ;

Nunez, Julio ;

Rodriguez-Manero, Moises ;

Cosin-Sales, Juan ;

Ramon Gonzalez-Juanatey, Jose ;

Quiles, Juan ;

Bertomeu-Martinez, Vicente .

EXPERT OPINION ON PHARMACOTHERAPY, 2011, 12 (10) :1473-1479

[46] How I use anticoagulation in atrial fibrillation [J].

Steinberg, Benjamin A. .

BLOOD, 2016, 128 (25) :2891-2898

[47] Anticoagulation in Atrial Fibrillation and Rheumatic Heart Disease [J].

Lip, Gregory Y. H. .

NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (11) :1036-1038

[48] An Update on Anticoagulation in Atrial Fibrillation [J].

Amerena, John ;

Ridley, Daryl .

HEART LUNG AND CIRCULATION, 2017, 26 (09) :911-917

[49] Anticoagulation in nonvalvular atrial fibrillation [J].

Nagra, Bipinpreet S. ;

Kantharia, Bharat K. .

FUTURE CARDIOLOGY, 2005, 1 (03) :373-380

[50] Stroke Prevention in Atrial Fibrillation [J].

Piccini, Jonathan P. ;

Wallace, Thomas W. ;

Patel, Manesh R. ;

Becker, Richard C. .

CARDIOVASCULAR DRUGS AND THERAPY, 2011, 25 (06) :561-570

← 1 2 3 4 5 →